

SUMMARY

## General approach to and summary of the guideline for the management of atopic dermatitis

R J Green,<sup>1</sup> MB BCh, DCH, FCP (SA), DTM&H, MMed, FCCP, PhD, Dip Allergology (SA), DSc; W Sinclair,<sup>2</sup> MB ChB, MMed (Derm)

<sup>1</sup> Department of Paediatrics and Child Health, Faculty of Health Sciences, University of Pretoria, South Africa

<sup>2</sup> Department of Dermatology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa

Corresponding author: W Sinclair (sinclairw@ufs.ac.za)



### General approach to the treatment of atopic dermatitis

#### Mild dermatitis

- Appropriate general measures
- Emollients
- Weak to moderately potent topical corticosteroids (TCSs) depending on body site
- Topical calcineurin inhibitors (TCIs) as second line or where corticosteroids are contraindicated

#### Moderate dermatitis

- Appropriate general measures
- Emollients
- Moderate-potency TCSs for maintenance
- Potent TCSs for flares
- TCIs (tacrolimus or pimecrolimus) as maintenance for selected skin areas
- Sedating antihistamines

#### Severe dermatitis

- Appropriate general measures
- Emollients
- Potent TCSs
- TCIs (tacrolimus only) on selected skin areas

#### Acute flares

- Systemic corticosteroids (short courses)
- Moderately potent to potent TCSs in hospital
- Sedating antihistamines
- Thereafter, maintenance as for chronic disease

#### Chronic disease

- Ultraviolet (UV) light
- Non-steroidal systemic drugs: azathioprine, cyclosporin, methotrexate, mycophenolate

#### Severe refractory cases, frequent flares, poor response, moderate dermatitis in young patients

- Refer to dermatologist/paediatrician/allergist as appropriate
- Potent TCSs
- Phototherapy (narrow-band UVB)
- Cyclosporin, methotrexate, oral corticosteroids, azathioprine, mycophenolate mofetil, intravenous immunoglobulin, interferon-gamma
- Psychotherapeutic intervention

